ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
First Claim
1. A method for the prophylaxis or treatment of a RSV or parainfluenza virus infection in a subject, comprising administering to a subject in need of such treatment a therapeutically effective amount of a pharmacological acceptable oligonucleotide of at least 20 nucleotides in length, wherein said oligonucleotide comprises at least 19 phosphorothioated linkages, does not comprise a CpG motif, does not have a complement in the genomic sequence of RSV or parainfluenza virus, and wherein the anti-viral activity of said oligonucleotide occurs principally by a non-sequence complementary mode of action.
1 Assignment
0 Petitions
Accused Products
Abstract
Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.
99 Citations
18 Claims
- 1. A method for the prophylaxis or treatment of a RSV or parainfluenza virus infection in a subject, comprising administering to a subject in need of such treatment a therapeutically effective amount of a pharmacological acceptable oligonucleotide of at least 20 nucleotides in length, wherein said oligonucleotide comprises at least 19 phosphorothioated linkages, does not comprise a CpG motif, does not have a complement in the genomic sequence of RSV or parainfluenza virus, and wherein the anti-viral activity of said oligonucleotide occurs principally by a non-sequence complementary mode of action.
Specification